乙甲基脱酶1A1的上调会通过线粒体功能障碍和角质细胞亡导致达科米替尼布诱导的皮肤毒性
Wanying Zhou1, Xinyue Ma1, Lili Tan1
1Postgraduate training base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, Zhejiang 310022, China; Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China.
达科米蒂尼布通过ALDH1A1酶损害角质细胞,引起皮肤毒性. 向ALDH1A1可以预防或治疗非小细胞肺癌患者的这种副作用.
科学领域:
- 在瘤学瘤学.
- 皮肤病学 皮肤病学
- 分子生物学分子生物学
背景情况:
- 达科米替尼 (dacomitinib) 是一种全人类表皮生长因子受体 (HER) 氨酸激酶抑制剂 (TKI),可治疗EGFR突变非小细胞肺癌 (NSCLC).
- 皮肤毒性限制了dacomitinib的使用,未知机制阻碍了有针对性的干预措施.
研究的目的:
- 为了研究达科米替尼布诱导的皮肤毒性的机制.
- 确定潜在的治疗点,以减轻达科米提尼布的皮肤副作用.
主要方法:
- 建立了达科米替尼布诱导皮肤毒性的动物模型.
- 分析了达科米替尼对状细胞线粒体功能,亡和炎症因子分泌的影响.
- 研究了视网体通路和乙甲脱酶1A1 (ALDH1A1) 在毒性的作用.
- 评估了ALDH1A1倒置和西利比宁治疗的治疗潜力.
主要成果:
- 达科米替尼布诱导了线粒体功能障碍,亡和角质细胞的炎症.
- 达科米蒂尼布激活了视网质通路,从而调节了ALDH1A1,这是皮肤毒性的关键因素.
- ALDH1A1倒置改善了达科米替尼布诱导的角质细胞损伤.
- 西利比宁通过降低ALDH1A1.1.的调节,减少了达科米替尼布诱导的皮肤毒性.
结论:
- ALDH1A1在达科米替尼布诱导的皮肤毒性中发挥着关键作用.
- ALDH1A1代表了一种潜在的治疗点,用于管理dacomitinib在NSCLC患者的皮肤副作用.
更多相关视频
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
07:14A Flow Cytometry-based Assay for Measuring Mitochondrial Membrane Potential in Cardiac Myocytes After Hypoxia/Reoxygenation
Published on: July 13, 2018
相关概念视频
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
The Intrinsic Apoptotic Pathway
![Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F60445.jpg&w=3840&q=50)